G Amphray Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.95 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.10 M
as on 23-10-2024
- Company Age 42 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 70.07%
(FY 2023)
- Profit 78.16%
(FY 2023)
- Ebitda 79.50%
(FY 2023)
- Net Worth 35.65%
(FY 2023)
- Total Assets 19.09%
(FY 2023)
About G Amphray Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.95 Cr and a paid-up capital of Rs 1.10 M, as per Ministry of Corporate Affairs (MCA) records.
Grace Deora, Rajesh Deora, and Rajiv Deora serve as directors at the Company.
- CIN/LLPIN
U24200MH1982PTC026504
- Company No.
026504
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Feb 1982
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at G Amphray Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Grace Deora  | Director | 03-Sep-2006 | Current |
| Rajesh Deora | Director | 21-Jun-2005 | Current |
| Rajiv Deora | Director | 27-Dec-1990 | Current |
Financial Performance of G Amphray Pharmaceuticals.
G Amphray Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 70.07% increase. The company also saw a substantial improvement in profitability, with a 78.16% increase in profit. The company's net worth Soared by an impressive increase of 35.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of G Amphray Pharmaceuticals?
In 2023, G Amphray Pharmaceuticals had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Triochem Laboratories Pvt LtdActive 42 years 10 monthsGrace Deora, Rajesh Deora and 1 more are mutual person
- Ambernath Plasto Packaging Pvt LtdActive 32 years 1 month
Grace Deora, Rajesh Deora and 1 more are mutual person
- Deora Investments Private LimitedActive 30 years 11 months
Grace Deora and Rajiv Deora are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at G Amphray Pharmaceuticals?
G Amphray Pharmaceuticals has a workforce of 20 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of G Amphray Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped G Amphray Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
